Sign in
WithdrawnNo phase

Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer

Key facts

Who runs it
First Affiliated Hospital Xi'an Jiaotong University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 May 2024
Ended
19 Jul 2024
Type of study
Observational, 2 groups
Treatments tested
  • CTPA (computed tomography pulmonary angiography)
Record updated
22 July 2024
Why it stopped
The number of patients is not sufficient to support the project.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • The pathological diagnosis was lung cancer
  • Pulmonary artery was evaluated by CTA during hospitalization

Who cannot take part

  • Patients with a history of PE before diagnosis of lung cancer
  • Patients with incomplete clinical data
  • Patients with no follow-up data

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.

The 2 groups in the trial

  • PE group

    The CTPA diagnosis suggest pulmonary embolism

    Treatment: CTPA (computed tomography pulmonary angiography)

  • control group

    The CTPA diagnosis did not suggest pulmonary embolism

    Treatment: CTPA (computed tomography pulmonary angiography)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 July 2024